Španija - španščina - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - meloxicam - comprimido - 7,5 mg - meloxicam 7,5 mg - meloxicam

Španija - španščina - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - risedronato sodio - comprimido recubierto con pelÍcula - 35 mg - risedronato sodio 35 mg - Ácido risedrónico

Španija - španščina - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - tolterodina tartrato - cÁpsula dura de liberaciÓn prolongada - 4 mg - tolterodina tartrato 4 mg - tolterodina

Evropska unija - španščina - EMA (European Medicines Agency)

mylan s.a.s. - pregabalina - anxiety disorders; neuralgia; epilepsy - los antiepilépticos, - epilepsypregabalin mylan pharma está indicado como terapia adyuvante en pacientes adultos con crisis parciales con o sin generalización secundaria. de ansiedad generalizada disorderpregabalin mylan pharma está indicado para el tratamiento del trastorno de ansiedad generalizada (tag) en adultos.

Evropska unija - španščina - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agentes antitrombóticos - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evropska unija - španščina - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - bloqueo neuromuscular - todos los demás productos terapéuticos - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Evropska unija - španščina - EMA (European Medicines Agency)

mylan s.a.s - ritonavir - infecciones por vih - antivirales para uso sistémico - ritonavir está indicado en combinación con otros agentes antirretrovirales para el tratamiento de pacientes infectados con vih 1 (adultos y niños de 2 años en adelante).

Španija - španščina - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - ritonavir - excipientes: sorbitan, laurato de,cloruro de sodio,fumarato de estearilo y sodio,polisorbato 80 - antivirales de acciÓn directa - inhibidores de proteasa - ritonavir

Španija - španščina - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - lamivudina; zidovudina - comprimido recubierto con pelÍcula - 150 mg/300 mg - lamivudina 150 mg; zidovudina 300 mg - zidovudina y lamivudina

Španija - španščina - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan pharmaceuticals, s.l. - betametasona 17-valerato, fusidico acido - excipientes: clorocresol,hidrogenofosfato de sodio dihidrato,hidroxido de sodio (e-524),cetoestearilico, alcohol - corticosteroides en combinaciÓn con antibiÓticos - corticosteroides potentes en combinación con antibióticos - betametasona con antibióticos